9 results about "Aneurysm dissecting" patented technology

The invention discloses gamma-aminobutyric acid and application of a pharmaceutical composition thereof in preparation of drugs for preventing or treating aortic dissection and aortic aneurysm. The invention provides the application of gamma-aminobutyric acid in preparation of drugs for preventing or treating aortic dissection for the first time, and verifies the application of gamma-aminobutyric acid in preparation of drugs for preventing and / or treating aortic dissection and aortic aneurysm by inhibiting endothelial cell dysfunction; the application of gamma-aminobutyric acid in preparation of drugs for preventing and / or treating aortic dissection and aortic aneurysm by inhibiting expression of c-FOS to reduce vascular endothelial cell injury is verified; the application of gamma-aminobutyric acid in preparation of drugs for preventing and / or treating aortic dissection and aortic aneurysm by reducing infiltration of macrophages is verified.

The invention provides lipid nanoparticles taking zinc phosphate as an inner core, a preparation method of the lipid nanoparticles and a medicine for treating aortic aneurysm, and relates to the technical field of biological medicines. The lipid nanoparticles provided by the invention comprise zinc phosphate nanoparticles, DOPA (Dioctyl-Phthalate Polyamide), ionizable cationic lipid, cholesterol and PEG (Polyethylene Glycol) lipid, the zinc phosphate nano-particles are inner cores of the lipid nano-particles. The lipid nanoparticles have excellent biocompatibility and safety and stable structure, and can improve the stability and delivery efficiency of nucleic acid (such as FBN1mRNA) as a carrier, thereby realizing effective treatment of diseases. According to the medicine for treating the aortic aneurysm, provided by the invention, accurate delivery of FBN1mRNA and expression in FBN1 cells can be realized, and angiogenesis and repair are promoted, so that accurate treatment of the aortic aneurysm is realized.

An axially compressible bare stent for an aorta, formed by interleaving at least two wires having different diameters, i.e., a first wire and a second wire, in an overlapping manner. In a natural release state, the bare stent has a metal coverage of at least 30%. The first wire has a diameter of 20-150 μm, and the second wire has a diameter of 150-600 μm. During the use in the treatment of aortic aneurysms and / or aortic dissection lesions, low liquid permeability and a strong radial support force are provided at a desired location in an aorta by means of the axial compressibility of the bare stent.

The invention discloses application of KAT7 as a target spot in treatment of aortic aneurysm and dissection. According to the application, an AngII-induced aortic aneurysm mouse model is applied, the treatment effect of the KAT7 inhibitor WM3835 on aortic aneurysm / dissection is detected through mouse survival rate, aortic aneurysm occurrence rate, aorta width, blood vessel staining and WB staining indexes, and the WM3835 can slow down the occurrence and progress of aortic aneurysm, reduce the occurrence of aortic dissection and improve the survival rate of aortic aneurysm / dissection, so that the KAT7 inhibitor WM3835 can be used for treating aortic aneurysm / dissection. And a new target and a new medicine are provided for clinically treating aorta and dissection of aortic aneurysm. The KAT7 inhibitor WM3835 provided by the invention is a brand new drug treatment means for treating aortic aneurysm and dissection, is an important supplement for operative treatment of aortic aneurysm / dissection, and has important clinical significance.

Various concepts involve an iliac bifurcation prosthesis extending a length between the proximal and distal ends, which bifurcates from the main flow channel into two flow channels. Various concepts also involve methods for deploying an in-situ prosthesis system to treat aortic aneurysms, including deploying the iliac bifurcation prosthesis into the ipsilateral leg of the bifurcation main prosthesis or into the contralateral opening of the bifurcation main prosthesis.

The invention relates to the field of animal models, in particular to sgRNA for preparing an aortic aneurysm animal model and a preparation method, and the sgRNA is characterized in that a TB structural domain of an exon 57 part of an FBN1 gene is knocked out on Bama miniature pig cells through a CRISPR / Cas9 gene editing method. The important structural domain of the FBN1 gene and the TB structural domain of the exon 57 part are screened out by deeply analyzing the structure and the function of the FBN1 gene and combining bioinformatics prediction and disease model related research. The prepared Bama miniature pig subjected to specific gene editing is expected to show unique value in medical research, disease model construction or specific animal husbandry production application, and powerful support is provided for research and development of related fields.

The application relates to the technical field of biological medicine, and discloses an engineered exosome, a preparation method and purposes thereof. The method comprises the following steps: introducing an exogenous nucleic acid coding a human TIMP3 protein into endothelial progenitor cells to construct engineered cells, and obtaining exosomes by separating and purifying the supernatant after culture. The engineered exosome is secreted by the endothelial progenitor cells and is efficiently loaded with the TIMP3, and has both cell homing characteristics and protease inhibition functions. The exosome can significantly inhibit matrix metalloproteinase 3 (MMP3) activity, reduce extracellular matrix degradation, and improve the structural stability of a blood vessel wall. The application provides a novel and efficient cell-free delivery strategy for treating aortic dissection, aneurysm and other vascular remodeling diseases.

The invention discloses a mononuclear cell knapsack delivery system of targeted aortic dissection tissue as well as a preparation method and application of the mononuclear cell knapsack delivery system. A'mononuclear cell knapsack type delivery system 'is constructed, a drug is firstly wrapped in tiny vesicles or nanoparticles (NPs) and is non-covalently adhered to the surfaces of mononuclear cells through a reversible metal-polyphenol network formed by ferric ions, tannic acid and the like, and after intravascular administration, the mononuclear cells reach interlayer lesion tissues along with blood flow, so that the mononuclear cells can be quickly delivered to the surface of the mononuclear cells. The drug is migrated and enriched by chemotaxis of focus inflammatory factors, cell factors and the like, and the drug is released in a focus microenvironment, so that the purposes of actively targeting aortic dissection tissues and effectively treating aortic aneurysm and dissection are achieved. The mononuclear cell knapsack-type targeted delivery system provided by the invention does not destroy biological functions of mononuclear cells, can stably load nano-drugs and realize effective drug release in an interlayer or an interlayer early-stage lesion tissue, and shows a good clinical application prospect.

A pharmaceutical composition for preventing an aortic aneurysm is provided including a medium chain fatty acid as a main component, which has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, the composition through continuous intake can exhibit effects including inhibition of the progression of the aortic aneurysm and improvement in the vital prognosis.